1. Home
  2. CIF vs CING Comparison

CIF vs CING Comparison

Compare CIF & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Intermediate High Income Fund

CIF

MFS Intermediate High Income Fund

HOLD

Current Price

$1.71

Market Cap

31.1M

Sector

Finance

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$3.89

Market Cap

26.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIF
CING
Founded
1988
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.1M
26.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CIF
CING
Price
$1.71
$3.89
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.33
AVG Volume (30 Days)
43.9K
118.5K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
10.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.47
$3.20
52 Week High
$1.77
$6.01

Technical Indicators

Market Signals
Indicator
CIF
CING
Relative Strength Index (RSI) 42.21 51.45
Support Level $1.68 $3.82
Resistance Level $1.76 $4.02
Average True Range (ATR) 0.02 0.24
MACD -0.00 0.00
Stochastic Oscillator 21.43 37.36

Price Performance

Historical Comparison
CIF
CING

About CIF MFS Intermediate High Income Fund

Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: